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Abstract 
Mitochondrial reactive oxygen species (ROS) production has emerged as an 
important pathological mechanism in myocardial ischemia/reperfusion (IR) injury. 
Attempts at targeting ROS by scavenging using antioxidants have however been 
clinically disappointing. This review will provide an overview of the current 
understanding of mitochondrial ROS in IR injury. We will outline novel therapeutic 
approaches designed to directly target the mitochondrial respiratory chain and 
prevent excessive ROS production and its associated pathology. This approach 
could lead to more effective interventions in an area where there is an urgent need 
for new treatments.  
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Introduction 
Mitochondria are an important source of reactive oxygen species (ROS) in 
mammalian cells and play a critical role in cardiac function. Under physiological 
conditions, low levels of ROS are produced as a by-product of mitochondrial 
respiration and act as essential cellular mediators in a variety of biological processes 
including regulation of the immune response and autophagy1–3. Stress or injury can 
however cause ROS to increase significantly, overwhelming endogenous antioxidant 
mechanisms and resulting in severe oxidative damage to cellular components such 
as lipids, proteins and DNA4. Mitochondrial ROS are now known to be key mediators 
of mitochondrial dysfunction and disease pathology in a range of cardiovascular 
conditions including atherosclerosis, cardiac hypertrophy, chronic heart failure, 
ventricular remodeling and ischemia/reperfusion (IR) injury5–7. Upon reperfusion of 
ischemic myocardium, the rapid re-introduction of oxygen into the cell leads to a 
burst of ROS generation that triggers opening of the mitochondrial permeability 
transition (mPTP) pore and myocardial cell death. Significant progress has been 
made in the field of inhibiting or scavenging ROS in an attempt to preserve 
mitochondrial and cardiomyocyte function. However despite the large body of 
evidence supporting the inhibition of oxidative stress as a valuable therapeutic 
strategy, treatment with antioxidants has failed to deliver clinically significant 
benefits8. In the present review we will discuss the role of mitochondrial ROS in 
cardiac IR injury, describing the current mechanisms that are thought to drive its 
production. Furthermore we will highlight current methods at targeting mitochondria 
ROS production with a particular focus on interventions that inhibit complexes I and 
II.  
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Ischemia/reperfusion injury  
IR injury remains a leading cause of death worldwide and the primary cause of 
chronic heart failure (CHF). While the past few decades have seen a marked 
improvement in outcomes in patients treated with early reperfusion therapy, currently 
one in four patients will die or present with heart failure within one year post-injury9. 
Reperfusion of the ischemic myocardium is essential in order to salvage viable tissue 
but paradoxically the rapid restoration of blood flow can induce injury beyond that of 
the initial ischemic insult. Known as reperfusion injury, studies have shown that it can 
account for up to 50% of the total tissue damage7 for which there is currently no 
effective therapy available in the clinic. The mechanisms underlying IR injury are 
multifactorial and have been extensively reviewed elsewhere7,10. However, it is 
generally accepted that mitochondrial dysfunction is central to the pathology of both 
IR injury and CHF with the mitochondrion not only being the main producer of ROS 
but also a primary target of ROS damage.  
Cardiac metabolism is predominantly aerobic. As such the maintenance of 
normal cardiac function and viability is highly dependent on the constant delivery of 
oxygen. During periods of severe myocardial ischemia profound disturbances in 
metabolism occur resulting in a shift towards anaerobic glycolysis. ATP depletion and 
lactic acidosis drive cytosolic sodium accumulation via the sodium/hydrogen 
exchanger and as a consequence excess Na+ is extruded through the reverse action 
of the plasma membrane sodium/calcium exchanger11. Typical calcium (Ca2+) 
management by the sarcoplasmic reticulum Ca2+-ATPase (SERCA) is prevented, 
due to depletion of mitochondrially-derived ATP, resulting in cytosolic Ca2+ overload. 
Furthermore, there is an accumulation of metabolic end-products, including 
hypoxanthine, xanthine and succinate12–14, and the formation of pro-inflammatory 
mediators that promote the infiltration and activation of neutrophils. All these events 
are thought to ‘prime’ the heart for the large burst of ROS generation upon 
reperfusion. Re-oxygenation of the cell at reperfusion and rapid restoration of the 
mitochondrial membrane potential (Ψm) results in a large Ca
2+ influx into 
mitochondria. Together with a burst of ROS production 15 and normalization of pH16, 
opening of the mPTP is induced17. The prolonged opening of the mPTP is now 
generally agreed to be decisive in committing cells to death upon reperfusion. The 
mPTP is a highly conducting channel in the mitochondrial inner membrane. While the 
exact nature of the pore is under debate, recent evidence suggests that the FoF1-
ATP synthase is a major component18,19. While the low pH present during ischemia 
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prevents formation of the mPTP, the normalization of pH at reperfusion results in 
mPTP formation and subsequent collapse of Ψm, cytochrome c release, ATP 
depletion and cellular death. Opening of the mPTP is therefore a critical component 
in reperfusion injury pathology10,19–21. 
The mitochondrial electron transport chain is an important source of ROS 
during IR injury but several other sources can also contribute. They include 
monoamine oxidase (MAO) on the surface of the mitochondrial outer membrane, 
xanthine oxidases, NAD(P)H oxidases, and uncoupled nitric oxide synthases22–24. 
The contribution of these enzymes to total IR induced ROS production is however 
thought to be lower than that of mitochondria and to occur later in the IR injury 
process, so will not be discussed further in this review.   
 
The mitochondrial respiratory chain 
 Since this review is aimed at a general audience, a brief primer on 
mitochondrial respiratory activity is provided here, and is illustrated in Figure 1. 
Substrates (pyruvate from glycolysis or acetyl-CoA from β-oxidation) are 
decarboxylated in the tricarboxylic acid (TCA) cycle to yield reducing equivalents 
NADH and FADH2. Electrons are then passed onto complexes I or II respectively, 
and then to the mobile electron carrier co-enzyme Q10 (ubiquinone), reducing it to 
ubiquinol. Ubiquinol is re-oxidized by complex III, passing electrons to cytochrome c 
then cytochrome oxidase and finally oxygen, generating H2O. The respiratory 
complexes are electron-driven proton pumps, such that this passage of electrons is 
coupled to the generation of a trans-membrane proton electrochemical potential 
gradient (positive outside). The electrochemical energy in this gradient is then used 
by the FoF1-ATP synthase to generate ATP.  It is important to note that the sharing of 
Co-Q as a common electron carrier by complexes I, II, and III is what permits these 
complexes to exist in multiple configurations, such that electrons can flow from I to 
III, II to III, I to II, and II to I, as is shown in Figure 2. 
 
Central role of mitochondria  
Mitochondria are essential organelles for normal cellular function. Occupying up to 
30% of total cardiomyocyte volume, they are the main source of ATP for the 
contracting cell through oxidative phosphorylation25. Mitochondria are also a key 
source of cellular ROS production with oxygen being converted by mitochondria to 
superoxide at complexes I and III26, however while the amounts of superoxide 
produced by isolated mitochondria can be readily estimated, the amount produced in 
vivo and the factors that regulate this production remain obscure. The superoxide 
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produced in the mitochondrial matrix is then largely dismutated to hydrogen peroxide 
(H2O2) by manganese superoxide dismutase (Mn-SOD)
27.  While several other 
sources of ROS within mitochondria have been documented (e.g. -ketoglutarate 
dehydrogenase, monoamine oxidase, ETF-QOR of -oxidation, -glycoerophosphate 
dehydrogenase28,29, their relative importance under in vivo conditions is poorly 
understood. Thus, the rest of this review will focus primarily on complex I, as this 
appears to be quantitatively the most important source of ROS in the setting of 
ischemia reperfusion injury4.  
 
In the context of IR pathology elevated mitochondrial ROS levels drive 
oxidative damage to mitochondria, which results in disruption of the respiratory 
machinery and ATP generation. Additionally, in conjunction with dysregulated 
calcium levels, mitochondrial ROS lead to induction of the mPTP, contributing to both 
apoptotic and necrotic cell death due to IR. Because of the central role of 
mitochondrial ROS in IR pathology, many investigations have focused on 
characterizing the pathways that underlie their generation. In the past decade such 
studies have increasingly highlighted a central role for mitochondrial complex I as the 
most significant superoxide source during IR30,31. More recently, it has been shown 
that generation of superoxide from complex I during IR is dependent on electron 
supply from the mitochondrial citric acid cycle (CAC) intermediate succinate14. 
Succinate, which accumulates significantly during ischemia through the reverse 
action of complex II, is rapidly oxidized in the first minutes of reperfusion. This rapid 
oxidation drives reverse electron transport (RET) at complex I, in which electrons are 
forced from reduced Coenzyme Q (CoQ) back to complex I generating large 
amounts of superoxide. This process can be described as a ‘yin-yang’ formation in 
which during ischemia QH2 generated by complex I working forward, is oxidized by 
complex II working in reverse. At reperfusion, complex II acting in forward mode 
consumes the accumulated succinate driving RET at complex I (Figure 2). Most 
interestingly, from a therapeutic perspective, it has been shown that this generation 
of damaging ROS upon reperfusion can be inhibited, either by preventing the 
accumulation of succinate during ischemia, or by inhibiting the succinate-dependent 
superoxide production by transient inactivation of complex I14,32. Both approaches will 
be discussed further below.  
 
“Good” versus “bad” ROS 
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An intriguing aspect to ROS production in the heart is that depending on the 
circumstances and context, it can be considered either “good” or “bad”. That is, not 
all amounts of ROS are damaging and only when levels reach beyond the capacity of 
endogenous antioxidant mechanisms will ROS become detrimental to cell function 
and contribute to IR pathology. Conversely ROS production has also been found to 
be a trigger for protection against IR injury particularly through the activation of 
survival programs during ischemic pre- (IPC) and post-conditioning (IPost)33,34. IPC, 
first demonstrated by Murray in 198635, is a phenomenon in which brief cycles of IR 
protect the heart from reperfusion injury after a prolonged ischemic insult. ROS 
generated from these IR cycles are recognized as triggers for a cascade of signaling 
events that result in reduced tissue damage with the mitochondrion considered a 
primary source36. Pre-treating isolated rabbit hearts with oxygen radicals can 
reproduce the beneficial effect of IPC on infarct size37 while giving ROS scavengers 
prior to ischemia abolishes IPC-induced protection34. The most straightforward 
interpretation of this intriguing observation is that while low levels of ROS can be 
beneficial by up-regulating protective mechanisms, a larger amount of ROS amount 
has detrimental effects. This counter-balance between ‘good’ and ‘bad’ levels, known 
as “mitohormesis”2, is supported by an increasing body of work in which low levels of 
ROS are thought to act as signaling molecules to promote health and extend 
lifespan2. In the context of IR injury a small increase in ROS, sufficient to lead to 
transient mPTP opening, has been shown to be protective against subsequent IR 
injury38. On the other hand, prolonged ROS exposure leading to sustained mPTP 
opening inevitably leads to irreversible mitochondrial damage and ultimately cell 
death. The threshold at which ROS production transitions from being protective to 
becoming harmful may be modulated by a variety of factors such as diabetes, sex 
and age; risk factors which are already established to affect the efficacy of 
cardioprotective strategies39. For example, one way in which sex may determine the 
mPTP response to ROS, is in the levels of nitric oxide (NO).  It is known that eNOS is 
regulated by estrogen40, and this may directly impact ROS levels, in addition to NO 
being a direct inhibitor of the pore41. Similarly for aging, the sensitivity of the 
Keap1/Nrf2 signaling axis, a key genetic response to oxidative stress, is known to 
decline with age42. 
Another hypothesis explaining the protean roles of ROS could be ascribed to 
the spatial distribution of its sites of production. It is well established that for many 
signaling pathways the intracellular location of the signal plays a crucial role, for 
example the compartmentalization of the cGMP – guanylate cyclase pathway43. 
Unfortunately, the details of the localization of ROS signaling are difficult to assess in 
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vivo. However, given that different classes of mitochondria exist in the heart 
(subsarcolemmal versus intrafibrillar populations) behave differently during ischemic 
pre- and post-conditioning44,45, it seems likely that the spatial distribution of 
mitochondrial ROS generation may also be a key variable. Finally, the timing of ROS 
generation could be important during IR with ROS being beneficial as a trigger of 
preconditioning-like signaling before a prolonged period of ischemia, while the large 
ROS burst at reperfusion induces many detrimental downstream effects. 
 
Therapeutic implications: Preventing excessive ROS generation  
The compelling body of evidence linking reperfusion-induced ROS production to 
cardiac pathology has not surprisingly led to the testing of a wide range of anti-
oxidant approaches to mitigate the detrimental effects of oxidative stress upon 
reperfusion. While many antioxidant strategies have shown benefit when applied to 
in vitro and in vivo model systems, only a tiny fraction has translated to 
improvements in major clinical end-points in human trials46. For example, 
antioxidants including Vitamin C, Vitamin E, Edavarone and Coenzyme Q10 have 
shown disappointing or conflicting outcomes in patients8. Many possible reasons for 
these poor results have been considered; the dosage of drug may not be optimal to 
achieve sufficient myocardial levels at reperfusion, the timing of the intervention in 
relation to the onset of ischemia or point of reperfusion may be incorrect and pre-
clinical models used may not be appropriate for screening new compounds for 
human use47,48. The development of mitochondria-targeted antioxidants in which 
compounds are localized to the mitochondrion by conjugation to a 
triphenylphosphonium (TPP+) cation may address some of difficulties inherent in 
using un-targeted antioxidants that do not accumulate in mitochondria49. MitoQ is a 
TPP+ modified ubiquinol that upon delivery to mitochondria decreases oxidative 
damage and has been shown to be protective against both cardiac50 and liver IR 
injury51 in vivo as well as protecting against oxidative damage in a murine model of 
heart transplantation52. The potential benefit of these targeted compounds against IR 
injury in humans has yet to be determined. A further consideration is that a more 
effective strategy may be to block the excessive ROS production that occurs upon 
reperfusion at its source, rather than scavenge it after it has been produced. 
Moreover, this approach could in principle allow the blockade of ROS production only 
when it becomes pathological, avoiding the potential disruption to cellular 
homeostasis by altering physiologically important cellular signals by “good” ROS 
through chronic antioxidant treatment. Given that the mitochondrial respiratory chain 
is a critical source of ROS upon reperfusion, it has become a major target for novel 
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compounds aimed at ameliorating IR injury and this strategy will be discussed in the 
next section.  
 
Pharmacologic inhibitors of the respiratory chain as therapeutics for IR injury. 
Despite the lack of oxygen during ischemia or hypoxia leading to inhibition of the 
respiratory chain, a wide variety of respiratory inhibitors have been demonstrated to 
afford protection against IR injury. Table 1 lists several such inhibitors and their sites 
of action within the respiratory chain. Until recently, it was thought the mechanism of 
action for these respiratory inhibitors was centered around the “gradual wake up” 
hypothesis of reperfusion therapy53. In this paradigm, a rapid reestablishment of 
respiratory activity at reperfusion leads to a surge of mitochondrial Ca2+ uptake and 
ROS generation which contribute to mPTP opening. It was hypothesized that the 
wash-out of a respiratory inhibitor present at reperfusion would permit a more 
gradual wake up of metabolism, thus avoiding these pathogenic effects. However, 
the recent identification of the source of ROS at reperfusion, namely the reverse 
electron transfer at complex I, forces a further focusing of this paradigm14. Namely it 
cannot go un-noticed that ~85% of the protective respiratory inhibitors listed in Table 
1 act at the level of complex I or II.  While the prevalence of agents hitting a given 
pharmacologic target cannot be taken as evidence of the central biological 
importance of the target, it is notable that there are well known inhibitors of other 
parts of the respiratory chain (e.g. cyanide for complex IV, myxothiazol for complex 
III) that have not been found useful in a therapeutic setting. Furthermore, while many 
of the molecules in Table 1 act at a pleiotropic level, there are some exquisitely 
specific drugs targeted at complexes I and II (e.g. rotenone and atpenin A5), which 
are most likely mediating their effects via these complexes and not through off-target 
mechanisms. We will now discuss these complexes in turn and the current evidence 
for their modulation in protecting the myocardium during IR injury.  
 
Complex I  
Complex I (NADH ubiquinone oxidoreductase) is the primary point of electron entry 
within mitochondria responsible for the oxidation of NADH, derived from glycolysis, 
the CAC and the β-oxidation of fatty acids. Complex I transfers electrons to CoQ and 
protons are transported across the inner membrane contributing to the mitochondrial 
proton motive force. In addition it is an important site for ROS generation with 
complex I producing large amounts of superoxide in the presence of a high 
NADH/NAD+ ratio where oxygen reacts with a fully reduced flavin mononucleotide 
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(FMN) site4. Complex I can also produce a large amount of ROS during RET where, 
in the presence of a highly reduced CoQ pool and a close to maximal proton motive 
force, electrons are pushed backward from CoQH2 through complex I reducing NAD
+ 
to NADH and also producing superoxide54,55. While the physiological relevance of 
RET in vivo is only now being elucidated it produces the largest rate of mitochondrial 
ROS production known to occur within mitochondria. Furthermore, this process of 
superoxide production by RET at complex I seems to be the major source of ROS 
early during IR injury14. 
During prolonged ischemia, when complex I is not oxidizing NADH due to the 
lack of oxygen, the protein converts to a ‘deactive’ state56,57. Reperfusion of the 
tissue results in the rapid re-activation of complex I and the generation of large 
amounts of cytotoxic ROS by RET14. Inhibitors of complex I including rotenone31 and 
amobarbital58 have found to be protective when given during cardiac IR injury 
indicating that preventing the reactivation of complex I upon reperfusion is a 
promising potential therapeutic strategy. Of course, the use of irreversible complex I 
inhibitors is not viable as a therapy, but interestingly when complex I undergoes the 
‘deactive’ transition a critical cysteine, cysteine 39 on the ND3 subunit becomes 
exposed to modification56,57. This residue can be reversibly inhibited by its S-
nitrosation by S-nitrosothiols such as SNO-MPG59 or MitoSNO32. Further supporting 
a role for this cysteine residue in cardioprotection, recent work has shown that 
damage protection during IR, IPC and IPost correlates highly with the persistent S-
nitrosation of mitochondrial protein thiols, with complex I as a chief target32,60–62. One 
example of this protective mechanism is MitoSNO, a mitochondria-targeted drug that 
prevents ROS production from complex I during early reperfusion following IR 
injury32. MitoSNO is a mitochondria-targeted S-nitrosothiol based on the NO donor S-
nitroso-N-acetylpenicillamine (SNAP) coupled to the TPP+ cation which leads to its 
rapid, several hundred-fold accumulation, driven by both the plasma and 
mitochondrial membrane potentials, into the mitochondrial matrix where it 
accumulates within minutes of intravenous injection63,64. Upon uptake into 
mitochondria MitoSNO reacts rapidly with intra-mitochondrial thiols and S-nitrosates 
cysteine 39 on subunit ND3 of complex I “locking” the enzyme in its de-active form at 
reperfusion and thereby preventing the excessive burst of ROS upon reperfusion32. 
The modification is reversed with a half-life of ~5 min by the endogenous 
mitochondrial glutathione and thioredoxin systems, allowing complex I to return to full 
levels of activity a few minutes after reperfusion14. Our studies have shown that 
MitoSNO not only protected against IR injury in vivo32 but also greatly enhanced 
long-term cardiac function post-IR injury65. 
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Complex II  
Complex II (succinate dehydrogenase) catalyzes the oxidation of succinate to 
fumarate resulting in the donation of electrons to the respiratory chain via the 
reduction of FAD to FADH2. Unlike the other respiratory complexes, it does not pump 
protons across the inner membrane but instead acts to maintain a reduced CoQ pool 
which has been largely considered to be its primary function66. This sequence also 
creates a direct link between two major mitochondrial pathways, the CAC and the 
respiratory chain. Several roles for complex II have however also been recently 
proposed that expand beyond this with evidence now for direct complex II-mediated 
ROS generation67 as well as a mechanistic link with the putative mitochondrial ATP-
sensitive potassium channel (mtKATP)
68. Complex II is also now recognized as a key 
modulator of mitochondrial ROS production by other respiratory complexes, 
particularly complex I.  
The accumulation of excessive ischemic succinate, via the reverse action of 
complex II, is considered a critical driver of ROS formation at reperfusion. Preventing 
either its build-up during ischemia or its rapid oxidation at reperfusion are therefore 
potential valuable therapeutic strategies to reduce detrimental ROS generation and 
protect against IR injury. In agreement with this an extensive body of work exists 
demonstrating the inhibition of respiration at complex II can decrease ROS 
production69. Inhibitors such as dimethyl malonate, diazoxide and atpenin A5 all 
protect against IR injury when given prior to ischemia14,70–72. Moreover protection 
afforded by dimethyl malonate in vivo was attributed directly to the attenuation of 
ischemic levels of succinate and inhibition of mitochondrial ROS generation at 
reperfusion14. There is also some evidence that malonate itself may act as an 
endogenous protector against IR with the compound being generated endogenously 
in mitochondria under conditions mimicking IPC73. However whether these 
compounds exert cardioprotective effects solely via complex II inhibition and ROS 
generation or if the mtKATP channel is involved remains a controversially and actively 
discussed issue. Moreover, while these strategies may be highly useful in situations 
of predictable ischemia, including elective surgery and organ transplantation, they 
are not clinically appropriate given patients undergoing an myocardial infarction (MI) 
arrive at hospital with an already occluded artery. Succinate accumulation during 
ischemia only becomes pathological upon its rapid oxidation at reperfusion in which it 
drives RET-mediated ROS production through complex I. By suppressing succinate 
oxidation at the point of reperfusion through complex II inhibition, compounds such 
as dimethyl malonate could be potentially cardioprotective. It is therefore essential to 
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determine if complex II inhibitors are as equally effective at ameliorating cardiac 
injury when used later in IR such as just prior to reperfusion. Indeed recent work in 
the isolated mouse heart has demonstrated that the administration of malonate 
during the first 15 min of reperfusion only was cardioprotective through the inhibition 
of succinate re-oxidation and the reduction in ROS production and mPTP opening74. 
Whether this important result can be translated to in vivo models however remains to 
be determined.  
 
Future Perspectives & Translational Significance  
An important consideration for the potential future use of respiratory inhibition as a 
therapy for IR injury is the timing of delivery. While clearly the inhibition of complexes 
I or II at early reperfusion would be anticipated to minimize ROS generation from 
RET, it is not immediately clear that inhibition of these complexes during ischemia 
itself would be beneficial. This is because of the yin-yang nature of complexes I and 
II during ischemia in which complex I continues to operate as a proton pump allowing 
to some extent the ∆Ψm to be maintained. As such, inhibition of complex I during 
ischemia may have unforeseen detrimental effects by removing this important 
function. A further consideration in moving such molecules into a clinical setting is 
their ease of wash-out, i.e. their tightness of binding to their targets. In the case of 
rotenone and other tight-binding lipophilic molecules, inhibition would be expected to 
reverse rather slowly, if at all, while the complex II inhibitor, 3-nitropropionate, is a 
“suicide inhibitor” that covalently modifies complex II potentially resulting in long term 
toxic effects on organ function75. Furthermore, currently available inhibitors of 
mitochondrial respiratory complexes are not tissue specific and are therefore present 
in other important tissues such as the brain. Consequently the chronic delivery of a 
respiratory inhibitor would be expected to elicit toxic side effects such as 
neurodegenerative disease. Specifically, long-term inhibition of complex I is 
associated with Parkinson’s disease, complex II Huntington’s disease, and complex 
IV Alzheimer’s disease76,77. In this regard, another advantage to nitric oxide donors 
and other short-lived species such as MitoSNO as mitochondrial respiratory 
inhibitors, is their short time of action and rapid metabolism, which would permit re-
establishment of “normal” mitochondrial function once the initial early-reperfusion 
danger-period has passed. 
Recently, it has been shown that treatment with a P2Y12 inhibitor, such as 
clopidogrel or ticagrelor, was highly protective in animal models of acute MI as well 
as in small human studies, and that many conditioning strategies, such as ischemic 
postconditioning do not offer additional benefits in reducing infarct size78,79. This 
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evidence could very well be the reason for the failures of many recent clinical trials of 
either ischemic postconditioning or interventions mimicking conditioning. In order to 
translate any of the above-mentioned compounds targeting complex I or III it is 
therefore crucial to test whether they have additive effects on top of an effective 
treatment with P2Y12 inhibitors
80.  Further aspects on how to translate preclinical 
findings into patient care and the challenges especially in acute MI have been 
extensively reviewed elsewhere81. 
 
Summary 
There is a pressing need for therapeutic approaches to be applied in conjunction with 
reperfusion therapy to reduce infarction injury and long-term outcome in MI patients. 
Modulation of the respiratory chain through inhibiting complex I and II are important 
emerging strategies. These interventions can now be considered as potential rational 
therapies, arising from the view that the initial burst of ROS from complex I upon 
reperfusion is due to the accumulation of succinate by the reversal of complex II 
during ischemia, that then drives the initial burst of ROS at reperfusion by RET at 
complex I. The reversible inhibition of complexes I and II would therefore prevent this 
burst of ROS and protect against infarction. Currently, approaches that prevent the 
accumulation of succinate during ischemia, such as dimethyl malonate, or stabilize 
the deactive form of complex I by S-nitrosation, such as MitoSNO, have been shown 
to be effective in animal models. Whether these results will translate into the clinic 
remains to be seen. Certainly the next stages are to see if it is possible to extend and 
optimize these targets with new and better drugs. However the model of succinate-
driven ROS production mediated by complex I and II should facilitate the future 
development of novel targeted therapies against the generation of excessive 
mitochondrial ROS in a range of pathologies such as myocardial infarction and 
stroke. 
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Table 1 - Mitochondrial respiratory inhibitors that have been shown to protect 
the heart or brain from IR injury, and their sites of action. Note, some references 
are paired such that the phenomenon of a molecule inhibiting a respiratory complex, 
and the phenomenon of it being protective in IR injury, are not necessarily co-
observed in the same experimental system.  Inclusion of a molecule in this table 
should not be misconstrued as claiming that the mechanism of its protection is 
dependent on its effects on a given respiratory complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Site of action Inhibitor References 
Complex I Rotenone 31 
 Amobarbital 58 
 S-nitrosothiols 59,63,82,83  
 Nitrite 84,85  
 Metformin 86–89  
 Capsaicin 90,91 
 Isoflurane 92,93 
 
 
Ranolazine 94 
Complex II Atpenin A5 72 
 Diazoxide   71,95 
 Malonate 14,70,73  
 Nitroxyl 96,97 
 3-nitropropionate 98 
 
 
Nitro-alkenes 99 
Complex III 
 
Antimycin A 100 
Complex IV Nitric Oxide 101  
 Carbon Monoxide 102 
 Hydrogen Sulfide 103–105 
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Figure 1. The mitochondrial electron transport chain. Electrons derived from the 
oxidation of NADH and FADH2 enter the electron transport chain at complexes I 
(NADH ubiquinone oxidoreductase) and II (Succinate dehydrogenase). They are 
then funneled through the electron carriers, Coenzyme Q and complex III (Ubiquinol 
cytochrome c oxidoreductase), until they reach complex IV (cytochrome c oxidase) 
where they are used to reduce molecular oxygen to water. This transfer of electrons 
is coupled to the extrusion of protons at complexes I, III and IV generating an 
electrochemical gradient across the mitochondrial membrane. Protons in the 
intermembrane space are then used to drive the synthesis of ATP at complex V (ATP 
synthase). C = cytochrome c. Dashed arrows indicates path of electrons.  
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Figure 2. Respiratory Complex I & II “Yin-Yang” during ischemia & reperfusion. 
Under normoxic conditions, both complex I (red) and complex II (blue) work in the 
forward direction (dashed grey line indicates direction of electron flow), taking 
electrons from NADH and succinate respectively, and reducing ubiquinone (Q) to 
ubiquinol (QH2). Electrons are eventually passed down the respiratory chain to O2, 
and complex I pumps protons to generate a trans-membrane ΔpH. During ischemia, 
QH2 generated by complex I working forward, is oxidized by complex II working in 
reverse. In this “Yin-Yang” formation, fumarate acts as an electron acceptor, resulting 
in accumulation of succinate. This process allows complex I to continue pumping 
protons during ischemia. At reperfusion, the rapid consumption of accumulated 
succinate generates too much QH2 for the re-oxygenated terminal respiratory chain 
to handle (dotted line). Coupled with residual acidic pH from ischemia, this drives 
reverse electron transfer in complex I, resulting in the generation of significant 
amounts of ROS.  
 
